Literature DB >> 3942702

Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women.

M Akerlund, A Hauksson, S Lundin, P Melin, J Trojnar.   

Abstract

Three analogues of posterior pituitary hormones, 1-deamino-2-D-Tyr(OEt)-4-Val-8-Orn-vasotocin(dE-VVT), 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-vasotocin(dE-TVT) and 1-deamino-2-D-Tyr(OEt)-oxytocin(dE-OXY) were compared for their inhibitory effects on vasopressin (VP)-induced uterine activity in healthy women. At menstruation, during recording of intrauterine pressure (18 recording sessions in 11 women), intravenous infusion of lysine vasopressin (LVP, 1 ng/min/kg/body weight) induced an increase of the uterine activity and dysmenorrhoea-like symptoms. Intravenous injections of all analogues (10 micrograms/kg body weight) caused relief of symptoms and inhibition of uterine activity, dE-TVT was the most effective and dE-OXY was least active. With dE-TVT almost complete inhibition of contractions was seen during the first 10 min after injection. The duration of effect was also greatest with that analogue (40-50 min). Only dE-OXY had an agonist effect on spontaneous uterine activity. Pharmacokinetic studies of intravenous dE-TVT (10 ng/kg body weight) showed that the plasma half-life was approximately 16 min and the clearance 30 l/h. The bioavailability of 100 ng/kg given intranasally was about 5.5%. Further studies are recommended.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3942702     DOI: 10.1111/j.1471-0528.1986.tb07807.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  2 in total

Review 1.  Atosiban for preterm labour.

Authors:  Vassilis Tsatsaris; Bruno Carbonne; Dominique Cabrol
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Atosiban versus fenoterol as a uterine relaxant for external cephalic version: randomised controlled trial.

Authors:  Joost Velzel; Floortje Vlemmix; Brent C Opmeer; Jan F M Molkenboer; Corine J Verhoeven; Mariëlle G van Pampus; Dimitri N M Papatsonis; Joke M J Bais; Karlijn C Vollebregt; Liesbeth van der Esch; Joris A M Van der Post; Ben Willem Mol; Marjolein Kok
Journal:  BMJ       Date:  2017-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.